Logo image of ABVX.PA

ABIVAX SA (ABVX.PA) Stock Price, Quote, News and Overview

EPA:ABVX - Euronext Paris - Matif - FR0012333284 - Common Stock - Currency: EUR

7.35  -0.33 (-4.3%)

ABVX.PA Quote, Performance and Key Statistics

ABIVAX SA

EPA:ABVX (3/7/2025, 7:00:00 PM)

7.35

-0.33 (-4.3%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High15.42
52 Week Low5.62
Market Cap465.87M
Shares63.38M
Float57.20M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-24 2025-03-24/amc
IPO06-26 2015-06-26


ABVX.PA short term performance overview.The bars show the price performance of ABVX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

ABVX.PA long term performance overview.The bars show the price performance of ABVX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of ABVX.PA is 7.35 EUR. In the past month the price increased by 28.72%. In the past year, price decreased by -43.37%.

ABIVAX SA / ABVX Daily stock chart

ABVX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About ABVX.PA

Company Profile

ABVX logo image Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 62 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Company Info

ABIVAX SA

7-11 Boulevard Haussmann

Paris ILE-DE-FRANCE FR

Employees: 62

Company Website: https://www.abivax.com/

Investor Relations: http://abivax.com/investors/

Phone: 33153830963

ABIVAX SA / ABVX.PA FAQ

What is the stock price of ABIVAX SA today?

The current stock price of ABVX.PA is 7.35 EUR. The price decreased by -4.3% in the last trading session.


What is the ticker symbol for ABIVAX SA stock?

The exchange symbol of ABIVAX SA is ABVX and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ABVX.PA stock listed?

ABVX.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for ABIVAX SA stock?

12 analysts have analysed ABVX.PA and the average price target is 28.46 EUR. This implies a price increase of 287.18% is expected in the next year compared to the current price of 7.35. Check the ABIVAX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABIVAX SA worth?

ABIVAX SA (ABVX.PA) has a market capitalization of 465.87M EUR. This makes ABVX.PA a Small Cap stock.


How many employees does ABIVAX SA have?

ABIVAX SA (ABVX.PA) currently has 62 employees.


What are the support and resistance levels for ABIVAX SA (ABVX.PA) stock?

ABIVAX SA (ABVX.PA) has a support level at 6.73 and a resistance level at 7.64. Check the full technical report for a detailed analysis of ABVX.PA support and resistance levels.


Is ABIVAX SA (ABVX.PA) expected to grow?

The Revenue of ABIVAX SA (ABVX.PA) is expected to grow by 628.34% in the next year. Check the estimates tab for more information on the ABVX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABIVAX SA (ABVX.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABIVAX SA (ABVX.PA) stock pay dividends?

ABVX.PA does not pay a dividend.


When does ABIVAX SA (ABVX.PA) report earnings?

ABIVAX SA (ABVX.PA) will report earnings on 2025-03-24, after the market close.


What is the Price/Earnings (PE) ratio of ABIVAX SA (ABVX.PA)?

ABIVAX SA (ABVX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.2).


ABVX.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ABVX.PA. When comparing the yearly performance of all stocks, ABVX.PA is a bad performer in the overall market: 95.49% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ABVX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ABVX.PA. The financial health of ABVX.PA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABVX.PA Financial Highlights

Over the last trailing twelve months ABVX.PA reported a non-GAAP Earnings per Share(EPS) of -3.2. The EPS decreased by -10.5% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.37%
ROE -140.29%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%10.52%
Sales Q2Q%N/A
EPS 1Y (TTM)-10.5%
Revenue 1Y (TTM)N/A

ABVX.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ABVX.PA. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -6.86% and a revenue growth 628.34% for ABVX.PA


Ownership
Inst Owners41.83%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target28.46 (287.21%)
EPS Next Y-6.86%
Revenue Next Year628.34%